YAP1 and neoplasm: This deviation in functionality means some caution must be exercised when interpreting in vitro experiments that focus solely on YAP; for example, where YAP’s role as a tumour suppressor in cancer cells has been observed and validated via KD, it is possible that TAZ may have acted to compensate for loss of YAP via hyperactivation or increase expression, a phenomenon that has been observed in vitro and in vivo in the past [296,301,302].